These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20737807)

  • 1. [Expensive drugs and intergenerational justice].
    Hughes D
    Can J Public Health; 2010; 101(3):193-5. PubMed ID: 20737807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inter-provincial variation in government drug formularies.
    Grégoire JP; MacNeil P; Skilton K; Moisan J; Menon D; Jacobs P; McKenzie E; Ferguson B
    Can J Public Health; 2001; 92(4):307-12. PubMed ID: 11962119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The politics of access to expensive drugs: INESSS and the innovative pharmaceutical industry.
    Hughes D
    Healthc Policy; 2012 May; 7(4):35-40. PubMed ID: 23634161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dog's breakfast: prescription drug coverage varies widely across Canada.
    Anis AH; Guh D; Wang Xh
    Med Care; 2001 Apr; 39(4):315-26. PubMed ID: 11329519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions.
    Doshi JA; Li P; Puckett JT; Pettit AR; Raman S; Parmacek MS; Rader DJ
    Value Health; 2020 Feb; 23(2):209-216. PubMed ID: 32113626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.
    Brouwer ED; Basu A; Yeung K
    Pharmacoeconomics; 2019 Oct; 37(10):1287-1300. PubMed ID: 31270747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
    Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH
    J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dialogue. Prescription for problems? Capitating mental health drugs--the great debate.
    Docherty JP; Browne RA; Farmer M
    Behav Healthc Tomorrow; 1998 Oct; 7(5):32-8. PubMed ID: 10185199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of a national prescription drug formulary on prices, market share, and spending: lessons for Medicare?
    Huskamp HA; Epstein AM; Blumenthal D
    Health Aff (Millwood); 2003; 22(3):149-58. PubMed ID: 12757279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of incentive-based formularies on prescription-drug utilization and spending.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
    N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare reform through rationing.
    Floyd EJ
    J Healthc Manag; 2003; 48(4):233-41. PubMed ID: 12908223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluations in the canadian common drug review.
    Laupacis A
    Pharmacoeconomics; 2006; 24(11):1157-62. PubMed ID: 17067199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Politicians', bureaucrats' drug plans deemed too costly for public formularies.
    Kondro W
    CMAJ; 2007 Mar; 176(6):755. PubMed ID: 17353524
    [No Abstract]   [Full Text] [Related]  

  • 16. Ethical issues and access to healthcare.
    Trotochaud K
    J Infus Nurs; 2006; 29(3):165-70. PubMed ID: 16878859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Centralized drug review processes: are they fair?
    Mitton CR; McMahon M; Morgan S; Gibson J
    Soc Sci Med; 2006 Jul; 63(1):200-11. PubMed ID: 16427728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethical framework for resource allocation during a drug supply shortage.
    Gibson JL; Bean S; Chidwick P; Godkin D; Sibbald RW; Wagner F
    Healthc Q; 2012; 15(3):26-35. PubMed ID: 22986563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Product listing agreements (PLAs): a new tool for reaching Quebec's pharmaceutical policy objectives?
    Bourassa Forcier M; Noël F
    Healthc Policy; 2013 Aug; 9(1):65-75. PubMed ID: 23968675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approaches to rationing antiretroviral treatment: ethical and equity implications.
    Bennett S; Chanfreau C
    Bull World Health Organ; 2005 Jul; 83(7):541-7. PubMed ID: 16175829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.